These effects, together with a past report demonstrating that a small-molecule ACKR3 agonist CCX771 exhibits anxiolytic-like actions in mice,2 support the concept of targeting ACKR3 as a unique way to modulate the opioid process, which could open up new therapeutic avenues for opioid-relevant disorders. Importantly, these receptors had been https://gailr470wtp0.blogspothub.com/profile